The discovery of GLP-1, a hormone crucial for treating obesity and diabetes, emerged from unexpected research avenues, including a fishing expedition for unique pancreatic specimens. Key contributors, including Joel Habener and his colleagues, faced challenges due to NIH restrictions on animal research. Ultimately, the use of recombinant DNA technology and unconventional sources, like the anglerfish, led to breakthroughs that have significantly impacted the treatment landscape for cardiometabolic disorders affecting billions globally. This journey showcases the importance of fundamental research in achieving transformative medical therapies.
More than three decades after the discovery of GLP-1, the hormone has transformed the treatment of obesity, diabetes, and cardiometabolic disorders that affect more than a billion people worldwide.
The unique pancreas of an ugly fish helped accelerate a revolution in modern medicine.
It's just been one surprise after the next, Habener said. It's amazing to me.
The solution to the problem required a fishing expedition.
Collection
[
|
...
]